Navigating the future of Alzheimer’s care in Ireland - a service model for diseasemodifying therapies in small and mediumsized healthcare systems

A new class of antibody-based drug therapy with the potential for disease modification is now available for Alzheimer’s disease (AD). However, the complexity of drug eligibility, administration, cost, and safety of such disease modifying therapies (DMTs) necessitates adopting new treatment and care pathways.